Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study van Leeuwen, R.; Bonsel, G.J.; Reiss, P.; Danner, S.A.; Lange, J.M.A. 
Zidovudine treatment has considerable benefit in patients outcome and interpretation of the results in patients who had received prior antiretroviral treatment [5, 6] . While AIDS Cliniinfected with the human immunodeficiency virus (HIV), yet monotherapy with the drug does not prevent ultimate HIVcal Trials Group (ACTG) protocol 175 showed a clinical benefit for patients receiving zidovudine-didanosine treatment and sigrelated disease progression and death. Additive or sequential use of other antiretroviral agents has increased the options nificant improvements in CD4 cell parameters for patients in all combination arms, the European-Australian Delta-2 study for antiretroviral treatment. Combining drugs may provide the advantage of synergistic activity of drugs, while the emergence showed a less-pronounced benefit of combination therapy in patients previously treated with zidovudine. The most obvious of resistant viruses may be delayed (reviewed in [1, 2] ) and different cellular reservoirs of the virus may be targeted [3, 4] .
difference between the studies is the difference in the baseline CD4 cell count, which was just above 300 1 10 6 /L in ACTG A combination of antiretroviral agents may be administered to antiretroviral-naive patients or as additive treatment to patients 175 and just below 200 1 10 6 /L in Delta-2 [5, 6] . While there have been many reports of positive effects on who were previously treated with zidovudine monotherapy. Sequential therapy, that is, switching to alternative drugs, may immunologic and virologic parameters following first-line combination, additive, or sequential therapy with various antialso provide advantages over monotherapy, while toxicities may be reduced compared with that seen in combination treatretroviral agents [7 -11] , only few of them have addressed whether such treatment ultimately results in a more durable ment.
Recently, two large prospective studies that addressed the clinical benefit as judged by parameters such as disease progression and survival. impact of combination and additive treatment on the clinical outcome of HIV infection were completed. Although these As no other prospective studies are expected to generate estimates of the clinical benefits of combination and additive therapy, studies were consistent with respect to the effect of combination therapy in previously untreated patients, showing a marked there is a clear need for additional data on the optimal timing of these strategies. We analyzed data from an observational database benefit for patients receiving either a combination of zidovudine and zalcitabine or zidovudine and didanosine over zidovuof patients attending a large referral hospital in Amsterdam, many of whom had severe symptomatic disease and changed therapy dine monotherapy, there was a difference in the overall study because it was believed that they were refractory or intolerant to monotherapy with zidovudine. In this population with advanced disease, we determined the effects on survival of adding didano-JID 1997;175 (June) Therapy Changes in Advanced HIV Disease tients in whom zidovudine treatment was not effective (doses up Methods to 2.25 mg/day).
Patients. We included all HIV-1-infected patients attending
Laboratory methods. Blood was usually sampled in the mornthe outpatient clinic of the Academic Medical Centre in Amstering for the determination of the CD4 cell counts, which were dam, who started treatment with zidovudine monotherapy between measured by use of peripheral blood mononuclear cells isolated 1 January 1990 and 31 August 1994. Homosexual contacts were from heparinized venous blood by flow cytometry. This was qualthe predominant risk factor for HIV infection in this group. The ity controlled and performed according to standard methods. The hospital policy for prescribing antiretroviral treatment was based usual interval for measuring CD4 cells was every 3 months; other on the consensus guidelines of the Dutch AIDS treatment speciallaboratory measures were usually sampled on each visit. ists (reviewed in [12] ).
Data collection. The observational database that was used for Zidovudine was started in asymptomatic patients with CD4 cell this study was derived by combining several computer files with counts õ300 1 10 6 /L or in patients with CD4 cell counts õ400 laboratory and clinical information on these patients. The data have 1 10 6 /L and additional laboratory indicators of a poor prognosis been computerized both for purposes of patient care (in particular or symptoms of HIV disease. Patients could either start with zidolaboratory data) as well as for several research and surveillance vudine monotherapy or participate in one of the clinical trials in purposes (in particular such data as antiretroviral treatment and which they might receive double-blinded or open-label experimentime of death). The final database included all routine laboratory tal antiretroviral agents. The latter group of patients, who did not markers from these patients, as well as all AIDS-related illnesses start with zidovudine monotherapy, was excluded from the analyand the date of death or last follow-up. Most data were collected sis. However, patients who initially started zidovudine monotherprospectively. However, as hospital patients are often referred from apy and were subsequently included in one of these studies were other health care settings, chart abstraction to define the patients' not excluded from the analysis to avoid selection bias for evaluatbaseline status was allowed. ing the effect of subsequent treatment. The 1987 AIDS case definiStatistical analysis. Homogeneity of baseline characteristics tion for adults of the Centers for Disease Control and Prevention was established using the x 2 test for categorical variables and the (CDC) [13] was used. As this definition requires patients to be at Wilcoxon rank sum test or the Kruskal-Wallis test for continuous least 13 years of age, younger patients were excluded.
variables. Changes in antiretroviral treatment were usually based on a
Cox proportional hazards models were fitted using the PROC deterioration of a patient's health status, a significant drop in CD4 PHREG program of SAS software (release 6.03 for DOS; SAS cell count, or intolerance for zidovudine. Zidovudine was either Institute, Cary, NC). The primary outcome analyzed was survival, continued with the addition of didanosine or zalcitabine (additive defined as time from the start of zidovudine therapy (baseline) treatment) or discontinued and followed by the subsequent adminuntil death. Subjects were censored at the date of their last followistration of didanosine or zalcitabine only (sequential therapy).
up if alive at the end of the follow-up period, which was 31 For the purpose of the analysis, treatment groups were defined as December 1994. The significance of parameter estimates derived follows: patients who started additive therapy, patients who started from the proportional hazards models were tested with the Wald sequential therapy, and patients who continued zidovudine statistic [15] . monotherapy.
Once patients switched to either additive or sequential therapy, The use of acyclovir was limited to short-term treatments for continued use of the same treatment was presumed until death or herpes simplex virus infections only. Prophylaxis for Pneumocystis censoring. This method has been applied in other proportional carinii pneumonia (PCP) was strongly encouraged in all patients hazards modeling in HIV studies over the past few years [16] [17] [18] , with CD4 cell counts õ200 1 10 6 /L. Preferably, a once-daily dose because of its advantage of ignoring changes in therapy that occur of cotrimoxazole was used, while monthly pentamidine inhalations after the initiation of a therapy, which could bias estimates of were available for those patients who were cotrimoxazole-intolereffectiveness. The disadvantage of using this method is that potenant. A previous study has shown that in the Netherlands, complitial benefits can be masked or, alternatively, over-estimated if a ance with this regimen is very good [14] .
therapy change occurs more frequently in one of the study arms. The usual starting dosage of zidovudine during the study period Therefore, the number of patients who discontinued the antiretroviwas 200 mg three times daily or 250 mg twice daily. Didanosine ral treatment within each study arm was tabulated and tested. No became available in August 1990: at first within a double-blinded evidence was found for a selective discontinuation in one of the randomized study comparing two different dosages of the drug study arms. (750 vs. 200 mg/day; didanosine-ALPHA study), from October
The use of Cox proportional hazards models with updated mea-1991 onwards in a parallel-track program (dosages dependent on surements of the covariables provides a means to update the progbody weight, 375-750 mg/day), and from 1993 as a registered nosis of a patient on the basis of each new observation. Thus, the drug (standard dosage, 200 mg twice daily). Within the didanosinetiming of sequential or additive treatments is taken into account, ALPHA study, patients were required to be zidovudine-intolerant; which controls for survival bias: For example, a patient who surwithin the other programs, the drug could also be administered vives for a longer period may be more likely to receive (new) to patients whose condition was deteriorating during zidovudine treatment compared with the likelihood for a patient who has a monotherapy. Zalcitabine became available in the fall of 1991, shorter survival (reviewed in [19] ). Also, the inclusion of CD4 initially for a short period through a community-based HIV treatcell counts and other factors as time-dependent variables adjusts ment organization and later within an official parallel-track profor these prognostic factors at each time the treatment groups are compared. The method of complete time-dependent adjustment gram as monotherapy or in combination with zidovudine in pa-
04-02-97 09:39:20 jinfas UC: J Infect might, however, mask potential benefits of a switch in therapy, in mined significant (P õ .15) were retained in the model and were subsequently used to adjust the models that included the treatment case this benefit could be explained by changes induced by treatment in the variables that are used for adjustment of the models.
variables. The relatively high P value for inclusion of variables in the intermediate models was chosen so as not to miss potentially Therefore, additional models were constructed that adjusted until the change in therapy but were unadjusted thereafter.
important parameters that might be less significant because of the power of the study. Since the CD4 cell count has been wellThe following covariates with updated measurements were included in the models at monthly intervals from (and including) established as a predictive marker, we decided to include this variable in all multivariate models. Departures from the proporthe time of the first use of zidovudine: the presence of Kaposi's sarcoma without other AIDS-defining conditions (dichotomous: tionality assumption of the models were examined by multiplying the covariates with the log-transformed follow-up time (the log yes or no), presence of all other AIDS-defining conditions (i.e., including Kaposi's sarcoma simultaneously presenting with other scale was used because of the skewed distribution of the followup time) and testing whether these interaction variables had a AIDS-defining events, dichotomous: yes or no). The treatment variables were examined in two ways: One model included the significant contribution to the models. use of zalcitabine either as sequential or additive therapy (dichotomous: yes or no) and the use of didanosine also as additive or level was the primary predictive parameter for survival.
To investigate the influence of the duration of the preceding period
The clinical parameters were also first fitted in unadjusted of zidovudine use for the outcome with sequential or additive time-fixed and time-dependent models. The diagnosis of AIDS therapy, three time-dependent dummy variables were fitted repreand the age of the patient were both predictive for survival, senting categories of time since starting zidovudine (õ12 months, while the year of inclusion in the study was not ( A stepwise procedure to define statistically significant preuse of either additive or sequential therapies versus zidovudine alone (table 4) in unadjusted time-dependent models. The use dictors for survival resulted in a time-dependent model that included the following variables: CD4 cell count, the hemogloof both treatments was associated with increased probability of death. The other model included the use of didanosine or bin level, a diagnosis of AIDS (excluding those patients who presented with Kaposi's sarcoma only), and the age of the zalcitabine compared with the continued use of zidovudine monotherapy. Again, these changes in therapy were also associpatient (table 3) . The same variables were found when we constructed a time-fixed model in a stepwise procedure. The ated with an increased probability of death. To assess whether this poor prognosis of a change in therapy predictive value of the parameters in the final model was stable when individual variables were deleted from the model. may have been confounded by other factors, we examined different models that controlled for several prognostic variThe therapeutic variables were examined without and with adjustments of the models. First, we compared the effect of the ables. We first considered the adjustment for CD4 cell counts in time-dependent models. Both in the model that examined the use of either zalcitabine or didanosine and in the model /L were offered Pneumocystis carinii pneumonia prophylaxis; acyclovir was used intermittently for herpes simplex virus infections only. These two factors were therefore not used to adjust models. RH, relative hazard for death; CI, confidence interval.
* Fitted as time-fixed variate. † Excluding AIDS diagnoses based on Kaposi's sarcoma only.
ard for death compared with that in the unadjusted models. clinical status or laboratory indicators, which are associated with a poor survival. Adjustment of the models for the CD4 Subsequent adjustment in time-dependent models for hemoglocell count resulted in lower estimates of the risk for death bin levels, age, and the presence of AIDS-defining conditions after switching therapy compared with the estimates from the yielded models with similar relative hazards.
unadjusted models, but no survival differences were detected Although the adjustment for several prognostic variables is between the study groups. Nevertheless, a potential benefit necessary to deal with survivor bias, it might mask potential of a switch in therapy may have been overshadowed by a benefits of a switch in therapy, if this benefit could be explained deterioration of HIV disease in our patients, while additive and by increases in, for example, the CD4 cell count. To study this sequential treatment strategies might well be effective in other in more detail, we considered time-dependent models that were populations. Alternatively, increased toxicity of the combinaadjusted for the same set of prognostic variables until the tion of drugs in late-stage patients may also have contributed change in therapy and were unadjusted thereafter (table 4, rightto our findings. The absence of therapeutic benefit in late-stage hand column). By use of this method, we were not able to patients is in accordance with the recent demonstrations of the demonstrate any additional benefit of the therapy changes.
highly dynamic nature of HIV replication [24 -26], resulting Finally, we assessed whether the effect of alternative regiin increasing amounts of viremia during subsequent stages of mens would depend on the length of the preceding period of the infection [27, 28] . There are studies that provide support zidovudine monotherapy. This time-dependent model did not for these hypotheses. reveal any consistent or significant trend for an effect of the A study reported by Graham et al. [18] , who analyzed data duration of zidovudine treatment (data not shown). Similarly, for subjects within the Multicenter AIDS Cohort Study when we assessed whether other (potential) HIV treatments (MACS), showed that by use of time-dependent proportional might have biased our findings, we did not find that the use of hazards models adjusted for CD4 cell counts, platelet counts, these alternative treatments was predictive for survival (relative hemoglobin levels, HIV symptoms, PCP prophylaxis, and hazard, 1.07; 95% CI, 0.50 -2.31; P Å .85).
acyclovir use, a small decrease in the probability of death could be detected in patients who had changed zidovudine monotherapy to sequential or additive therapy with either zalciDiscussion tabine or didanosine. While this finding was statistically sigThe main conclusion of the study is that within this patient nificant, the absolute magnitude of this benefit was only estipopulation, no survival benefit of additive therapy with dimated at a maximum of 3 -6 months over continued zidovudine danosine or zalcitabine or for switching to monotherapy with monotherapy. these drugs could be demonstrated in patients who had initially A possible explanation for the seemingly different results in been treated with zidovudine monotherapy. In fact, unadjusted our study and the MACS analysis is the difference in baseline and partially adjusted models showed a small increased risk disease stage and the level of CD4 cell depletion at the start for death after switching therapy. Since an increased drop in of zidovudine monotherapy. The median CD4 cell count for CD4 cell counts was observed immediately before the switch the different treatment groups in the MACS analysis at baseline in therapy, this increased risk is likely to reflect that changes ranged from 284 to 342 1 10 6 /L, and all subjects were selected before the development of an AIDS-defining event. Although in therapy were often based on deterioration of a patient's / 9d2a$$ju09 04-02-97 09:39:20 jinfas UC: J Infect our hospital protocol allowed patients to start antiretroviral subjects who entered the study with a prior diagnosis of AIDS [30] . Similarly, a smaller study comparing sequential therapy therapy at CD4 cell counts below 300 -400 1 10 6 /L, the median CD4 cell count prior to the start of zidovudine therapy was with didanosine to continued zidovudine in patients who had used zidovudine monotherapy for at least 6 months showed a only 110 1 10 6 /L, while 128 (42%) of the patients were diagnosed with AIDS before the start of zidovudine therapy. This clinical benefit on progression to new AIDS-defining events or death for patients switching to didanosine; this benefit was difference between the hospital guidelines for starting treatment and the actual CD4 cell counts of patients at entry into the most apparent among patients with CD4 cell counts at entry of §100 1 10 6 /L [31]. Finally, the long-term follow-up of study reflects a referral bias: A hospital population selects for patients with later stages of HIV infection. Also, many patients study ACTG 019 on the effects of zidovudine monotherapy in asymptomatic patients suggested a more durable response in with higher CD4 cell counts did not start zidovudine monotherapy but were included in antiretroviral drug studies. Other difpatients with CD4 cell counts ú300 1 10 6 /L [32] . These studies provide cumulative evidence that successful ferences between both studies, such as the length of the study period, the frequency of follow-up visits within the study, the treatment of HIV infection may depend not only on the number of drugs that are used but also on the level of immunodeficiency number of study sites, differences with respect to the clinical care of HIV-infected patients (e.g., the type of PCP prophylaxis at which such treatment is initiated. Recent data on the changes in HIV RNA load during monotherapy with different nucleoused in the study period), and regional differences in CD4 cell measurements [29] , may all have contributed to the different side analogues (including zidovudine) show that substantial inhibition of the virus is seen only within a narrow treatment clinical and statistical findings of both studies.
It should be appreciated that the character of both studies window following the start of treatment [33 -35] . Therefore, a direct combination of drugs might be more effective than addiwas observational. The estimates that are provided by this study may be biased; therefore, the interpretation of our findings tive or sequential strategies, as is also suggested by studies that show that a combination of zidovudine and lamivudine in naive should be conservative. Yet, our study, as well as the analyses of the MACS cohort, is of key importance for the interpretation patients [36, 37] confers superior benefits on CD4 cell parameters compared with the addition of lamivudine in zidovudineof the different outcomes of two recently completed studies of combination treatment (ACTG 175 and Delta) [5, 6] , as no experienced patients [38, 39] . Preliminary findings from these studies have also suggested that initial suppression of viral other prospective studies are expected to further address the clinical outcome of combination therapy. The ACTG 175 study replication by use of the specific combination of zidovudine and lamivudine is more potent than the effects caused by the showed a statistically significant clinical benefit for zidovudine/ didanosine treatment in patients who had received prior antiretcombinations used in our analysis [39] . There may have been differential biases that could not be roviral treatment but not for zidovudine/zalcitabine treatment, although it might be argued that the point estimates of the successfully modeled either in this study or in the MACS study [18] . These could be responsible for the different findings of relative risks for both combination arms suggests a benefit over zidovudine monotherapy and that their confidence intervals are both studies. Another possible explanation for the lack of benefit in our study is that patients in this study switched therapy largely overlapping. The European-Australian Delta study, on the other hand, demonstrated only a modest benefit for either at advanced stages, whereas this switch may be more effective in early disease. This explanation will have important clinical of the combination arms [5, 6] .
The most obvious difference between both studies is the implications, as successful improvement of the effects of antiretroviral therapy, especially in, but probably not restricted to, baseline CD4 cell count at the start of additive therapy. The average CD4 cell count in the ACTG 175 study was 338 1 advanced HIV disease, will depend on a powerful combination of drugs [40, 41] . Preliminary results from studies with triple-10 6 /L, whereas in the Delta study it was just below 200 1 10 6 / L. Another indication that patients with less advanced disease combination therapy including protease inhibitors have shown that even in late-stage and pretreated patients, successful antimay benefit more from combination treatment comes from ACTG 155, which compared a combination of zidovudine and retroviral treatment has become possible [42] (reviewed in [43] ). Long-term efficacy studies on these regimens will be zalcitabine with either drug alone. This study did not demonstrate overall differences in progression rates. Nevertheless, a observational studies; for ethical reasons a randomized control arm can no longer be included. The methodology that is used subgroup analysis within this study suggested a clinical benefit in patients with CD4 cell counts ú150 1 10 6 /L [8] .
within our study may therefore be an important tool for the analyses of these and future studies. The above explanation for the differing outcome of antiretroviral treatment depending on the level of immunodeficiency is supported by other prospective studies. Study ACTG 116B/
